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INTRODUCTION
Treatment of patients with multiple myeloma (MM) is disappointing. In this regard, the SWOG experience on standard dose therapy in seven consecutive large phase III studies has shown median survivals of less than three years irrespective of the treatment given (1) . Also, the PETHEMA group found that increased doses of conventional chemotherapy did not result in a significant survival prolongation (2) . Finally, a metaanalysis including 6633 patients, from 27 randomized trials, failed to show a superiority of combination chemotherapy versus melphalanprednisone in terms of duration of response and survival (3) . Furthermore, the Nordic Myeloma Study Group reported no survival improvement in conventionally treated younger myeloma patients during the last two decades (4) . These limitations led to the current tendency to offer high-dose therapy/stem cell support (HDT) to MM patients as part of the front line treatment (5) . In this sense, two randomized trials conducted by the Intergroup Français du Myeloma (IFM) and the Medical Research Council (MRC) showed that HDT significantly increased complete remission rate, event-free survival (EFS) and overall survival (OS) as compared to conventional chemotherapy (5, 6) . However, two other randomized trials, reported in abstract form, have failed to show a superiority of autotransplantation (7, 8) . The objective of the present study was to investigate, in a prospective randomized trial, the efficacy of HDT intensification versus continuation with conventional chemotherapy in patients with MM who had responded to the initial chemotherapy. It should be noted that the design of this study is slightly different from the above mentioned IFM and MRC trials since primary refractory patients, were specifically excluded. The rationale for excluding this group of patients is that, it was our view, that early disease progression in patients while on their initial chemotherapy results in either early death or poor performance status precluding HDT in many of them and that in nonresponding patients but with non-progressive disease, the benefit of HDT is doubtful since the have a relatively good prognosis with conventional chemotherapy (9) .
PATIENTS AND METHODS

Patients and diagnostic criteria
Patients with newly diagnosed and untreated symptomatic stage II or III MM younger than 65
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From years with a performance status 0-2 were eligible for entering the study. From 1997 the upper age limit was extended up to 70 years. Two hundred and sixteen patients from 29 Spanish institutions were enrolled in the study between May 1, 1994 and October 31, 1999. Diagnosis of MM was made according to the criteria of the Chronic Leukemia-Myeloma Task Force (10).
The study was approved by the National Health Service and by all the local Institutional Ethic Committees. All patients gave written informed consent.
Study Design
All patients were given alternating courses of VBMCP/VBAD as initial chemotherapy. The For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From electrophoresis and less than 5% of bone marrow plasma cells. An objective or partial response was defined as 1) a reduction of 50% or more of the monoclonal protein in serum and/or urine, 2) improvement in performance status and 3) a decrease of greater than 50% in measured crosssectional area of plasmacytoma. Furthermore, the size and number of lytic bone lesions must not have increased, and there also must have been correction of hypercalcemia, anemia, and hypoalbuminemia. Those patients who fulfilled all the above criteria but who had a less than 50% reduction of M-protein were considered to have had a minimal response. When the criteria of CR, partial or minimal response were not accomplished, the case was considered as a treatment failure (10) . Very short transient responses observed during the first courses of treatment with subsequent relapse before the completion of the four courses were also considered as treatment failures.
Statistical Methods
The 2 test was used to assess the statistical significance of multiple comparisons. Overall survival (OS) was calculated from the start of the initial treatment to the date of death or last visit. Progression-free survival (PFS) was calculated from the day of initiation of treatment to the date of relapse or disease progression. Survival curves were plotted according to the method of Kaplan and Meier (11) and statistically compared by means of the log-rank test (12) .
Relationship between prognostic factors were determined by the Cox proportional hazards model for covariate analysis of censored survival date, using de SPSS software (13) . The variables at diagnosis included in the regression model were age, 2 microglobulin, serum albumin, hemoglobin level, M-protein type (IgA vs others) and treatment arm.
RESULTS
Response to initial chemotherapy
One-hundred and eighty five of the 216 patients (85%) responded to the initial chemotherapy.
The complete, partial and minimal response rates were 12%, 59%, and 14%, respectively.
Thirty-one of the 216 patients did not respond to the induction treatment. Among the nonresponders, seven died within the first months from the initiation of therapy, 14 received
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From different salvage chemotherapy regimens while 10 underwent HDT/SCT (9 autologous, 1 allogeneic). The outcome of the nine patients given autologous transplantation was partial response in six, failure in two and toxic death from haemorrhage in one. The patient who received an allogeneic graft achieved a transient CR. After relapse she was given donor lymphocyte infusion and she is currently in prolonged CR.
Randomization and comparability of treatment groups
One-hundred and sixty four of the 185 responders were randomized to receive eight additional courses of VBMCP/VBAD chemotherapy (arm A, 83 patients) versus HDT/SCT intensification (arm B, 81 patients, 24 received MEL-140/TBI and 57 were given MEL-200)). Twenty one responding patients were not randomized due to the following reasons: patient refusal (8 cases), co-morbid conditions (8 cases) and allogeneic transplantation (5 cases).
The pretreatment characteristics of patients according to treatment arm are shown in Table 1 . As it can be observed, presenting features were similar in both groups, except for a significantly higher proportion of patients with a hemoglobin level lower than 10 g/dL in the chemotherapy arm. Patients with a hemoglobin level lower than 10 g/dL had a significantly shorter survival than those with higher level in both treatment arms. Both groups were well balanced for 2- microglobulin serum levels and percentage of cells in S-phase. However, there was an imbalance in the M-protein type with a significantly higher number of patients with IgA myeloma in the HDT arm. In the present series, the survival of patients with IgA myeloma was not significantly different from that of those with other myeloma types. The presenting features showing prognostic significance at the univariate analysis were: serum 2-microglobulin (cut- The degree of response to the initial chemotherapy, immediately before randomization, was (Table 2 ).
Six patients in arm A did not completed the assigned treatment: five received an autologous transplant and one underwent an intensity dose-reduced allogeneic transplantation. Conversely, eight patients in arm B did not received the planned HDT followed by autologous stem cell support: four underwent allogeneic transplantation (conventional conditioning in two and intensity dose-reduced in two) while four did not receive any type of intensive therapy (two continued on alternating VBMCP/VBAD chemotherapy and two had aggressive disease progression before the planned HDT procedure could had been applied). As previously mentioned, the response to therapy and survival were analyzed in an intention-to-treat basis.
Response after completion of chemotherapy and after high-dose therapy Eight patients in arm A (9.6 %) showed disease progression before the completion of the 12 courses of chemotherapy. On the other hand, six patients in arm B (7.4 %) had disease progression within the 6 months following HDT intensification. In addition, three patients in arm A died in response before the completion of 12 courses of chemotherapy: one, who had indeed received HDT, died from pneumonia and respiratory failure 19 days after transplantation, while the other two died from miocardial infarction and neutropenic sepsis after 10 and 12 courses of chemotherapy, respectively. Also, three patients in arm B died before the response evaluation at 6 months after HDT, one toxic death from cerebral hemorrhage and the two who had indeed underwent allogeneic transplantation with conventional conditioning (one from graft versus host disease and one from multi-organ failure).
The complete remission rate 6 months after HDT was significantly higher than after the completion of the 12 courses of chemotherapy (30% vs. 11%, p= 0.002). The CR rates for patients receiving M·l-140/TBI and MEL-200 were 37% and 28% (P = NS), respectively.
Progression-free and overall survival
After a median follow-up of 56 months the median survival for the 216 patients included in the trial was 58 months. The median survival of the 31 patients who did not respond to the initial VBMCP/VBAD chemotherapy was 22 months. With a median follow-up of 66 months the median survival for all the 164 randomized responding patients was 65 months. As shown in 
Survival after relapse
Most patients received conventional rescue chemotherapy after relapse. In fact, only 10 patients in the chemotherapy arm received a rescue transplant and seven patients in the HDT group received a second transplant as salvage regimen. Finally, the survival after relapse was identical in the two arms (median, 15.9 vs 16.4 mos., Figure 3 ).
DISCUSSION
Despite the relative efficacy of the current anti-myeloma agents, the outcome of patients with MM is still unsatisfactory with a median survival of less than 3 years (14) . In addition, the proportion of long-term survivors with conventional chemotherapy is disappointingly small (15, 16) . Multiple myeloma is characterized by a high degree of resistance to therapy which results in a low CR rate with conventional chemotherapy. The fact that HDT can overcome tumor resistance inducing a CR rate ranging from 25 to 50% has stimulated the use of HDT followed by stem cell rescue as part of the up-front therapy in patients with MM. In this regard, one casecontrol (17) and two population-based control studies (18, 19) , have shown that patients given HDT survived significantly longer than those who received conventional chemotherapy.
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From However, data from randomized studies are limited. Thus, only two prospective randomized trials have shown the superiority of HDT/SCT in terms of EFS and OS (5, 6) while other two randomized studies, reported in abstract form, have shown that myeloablative therapy did not prolong survival when compared with conventional chemotherapy (7, 8) .
In line with almost all the reported studies on HDT versus conventional chemotherapy (5-7) we found that the high-dose regimen significantly increased the CR rate. However, we did not obtain a significant prolongation in EFS and OS with HDT when compared with continuing conventional treatment in patients responding to the initial chemotherapy. The main difference between our study and the above mentioned randomized trials is that in the present trial only patients with chemosensitive disease (i.e.: CR, PR or MR after 4 courses of chemotherapy) were included. In our study design it was considered that the crucial question concerning the possible impact of HDT as part of the initial therapy in myeloma patients is whether or not patients with MM sensitive to the initial therapy, which involves the majority of the myeloma population, might benefit from HDT intensification. While it is true that response to the initial chemotherapy selects by itself good prognosis patients, whether or not randomization at diagnosis could have resulted in significant differences in our trial is uncertain. In fact, the finding that in the present series the 2-microgloblin serum levels did not show prognostic influence at the multivariate analysis might be at least partially due to the fact that only patients who showed chemosensitive disease were randomized. Although it has been claimed that patient with primary resistant disease are the most likely to benefit from early high-dose therapy (20) , it is most important to recognize the heterogeneity of the two categories of refractory MM: i) those with primary unresponsive progressive disease and ii) those who show no significant change in the M-protein size with no clinical progression also called "non-responders, nonprogressors". Our rationale for excluding patients with primary refractory disease from randomization was that early disease progression while on the initial chemotherapy usually precludes HDT because of early death or poor performance status whereas patients with "nonresponding, non progressive disease" have a good outcome, likely due to a more indolent natural history of the disease, irrespective of the treatment given (9) . In fact, in all the studies in which the randomization was done at the initiation of the induction therapy, about one-fourth of the patients allocated to the HDT therapy arm did not receive such treatment mainly because of disease progression or poor performance status (5-7). In the present trial, in which only responding patients were randomized, less than 10% of the patients failed to receive the allocated treatment in each arm.
Aside from the time of randomization, there are other possible facts that could have accounted for the differences between our results and the trials reporting a significant benefit in favor of HDT. First, the dose intensity of our conventional arm, using the multialkylating-based regimen alternated with the non-cross resistant high-dose dexamethsone-containing VBAD regimen, is higher than in other trials. In this regard, in the MRC trial (6) patients allocated to the conventional arm received a median of only 6 cycles of ABCM while patients allocated to HDT were given a median of 5 cycles of C-VAMP, which is by itself more intensive than ABCM, plus HDT intensification with MEL-200. Concerning the IFM study (5) , the chemotherapy of the control arm consisted of alternating VCMP/VBAP, which contains lower doses of melphalan than the BVMCP and does not include high-dose dexamethasone. Supporting the possible impact of the chemotherapy arm, the authors of the US Intergroup study, in which no difference between HDT and continuation of conventional chemotherapy with BVMCP was found, claimed that the higher dose intensity with BVMCP, as compared with other standard regimens, could be the responsible for the lack of significant difference between HDT intensification and conventional chemotherapy (8) . Second, our maintenance therapy included not only interferon but also monthly high-dose dexamethasone. This more intensive maintenance therapy could have resulted in the longer progression-free survival observed in our series as compared with the other randomized studies (4-7), this diluting the possible influence of HDT. This notion is enforced by the fact that the median survival after relapse was of only 16 months in both arms compared with a median survival of about 2 years in patients relapsing after HDT in most series. Third, although it seems that the achievement of CR is the crucial step for a long-lasting disease control and overall survival in MM (21) (22) (23) , the fact that in our series the difference in the CR rate between the two arms was less than 20% could have also contributed to the lack of difference between HDT intensification and conventional chemotherapy in our study. Finally, the finding that the different events observed in each of the steps of our trial, including outcome after relapse, were virtually identical in the two arms, is an additional argument supporting the equivalent value of both treatment approaches. In fact, the median survival of about 5 years found in the present trial is similar to that reported by the PETHEMA Group (24) and by Alexanian et al (25) in patients with MM responding to the initial chemotherapy and who met the criteria for HDT intensification but who did not receive 
